MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report

BACKGROUND: Capmatinib, a potent and selective mesenchymalepithelial transition factor (MET) inhibitor, is an effective treatment option for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations or gene amplification. However, the mechanisms that confer resistance to capmat...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Wonyoung, Jeong, Kyung-Chae, Park, Seog-Yun, Kim, Sunshin, Kang, Eun Hye, Hwang, Mihwa, Han, Ji-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554684/
https://www.ncbi.nlm.nih.gov/pubmed/36248327
http://dx.doi.org/10.21037/tlcr-22-176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554684/
https://www.ncbi.nlm.nih.gov/pubmed/36248327
http://dx.doi.org/10.21037/tlcr-22-176

Ejemplares similares